Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00551512 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
A Phase 1 study of Cancer and Solid Tumors, sponsored by CanBas Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT00551512: Completed Phase 1 study of Cancer and Solid Tumors, sponsored by CanBas Co..
NCT00551512 is a Phase 1 study of Cancer and Solid Tumors that has completed, run by CanBas Co.. The registered enrollment target is 48 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00551512, a Phase 1 study of Cancer and Solid Tumors, has completed, sponsored by CanBas Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to find the answers to the following questions: 1. What are the highest doses of CBP501 and cisplatin that can be safely administered as consecutive 2-hours and 1-hour infusions every 21 days? 2. What are the side effects of the combination of CBP501 and cisplatin when given as an infusion every 21 days? 3. What amount of CBP501 and cisplatin are found in the blood at certain times after it is given? 4. Are there any substances in your blood or tumor that can tell us about tumor sensitivity to CBP501 and cisplatin? 5. Will CBP501 given with cisplatin help to treat your cancer?
Conditions Studied
Interventions
- DRUG CBP501 and Cisplatin
Study Locations (3)
Arizona
- Scottsdale Clinical Research Institute - Scottsdale
Massachusetts
- Dana Farber Cancer Institute - Boston
Nevada
- Nevada Cancer Institute - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
What the finished NCT00551512 record still lists
NCT00551512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which CBP501 and Cisplatin is the first listed.
NCT00551512 reports a single indexed study location in Arizona, Massachusetts, Nevada.
Frequently Asked Questions
What is clinical trial NCT00551512 about?
NCT00551512 is a clinical study titled "Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors". The purpose of this research study is to find the answers to the following questions: 1. What are the highest doses of CBP501 and cisplatin that can be safely administered as consecutive 2-hours and 1-hour infusions every 21 days? 2. What are the side effects of the combination of CBP501 and cispla...
What is the current status of trial NCT00551512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-11. Estimated completion is 2009-05.
What conditions does trial NCT00551512 study?
This clinical trial studies the following conditions: Cancer, Solid Tumors.
What interventions are being tested in trial NCT00551512?
The interventions under investigation include: CBP501 and Cisplatin (DRUG).
Who is sponsoring clinical trial NCT00551512?
This trial is sponsored by CanBas Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00551512 being conducted?
This trial has 3 study locations across Arizona, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00551512's enrollment target sits among peer trials
48 438th of 615 higher than 176 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia